Study: One-third of cancer chemotherapies employ off-label drugs

02/20/2013 | Yahoo

Approximately one-third of all cancer chemotherapies have not been approved by the FDA for that particular treatment, according to a new study. "The main criticism of off-label prescribing has been the concern that it jeopardizes patient safety because the full risk-benefit ratio is often not completely understood," wrote University of Toronto researcher Monika Krzyzanowska. The study did not examine the question of whether such off-label treatments are effective.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC